a life sciences biotechnology company with a mission to create novel values via biomarker discovery, development and regulatory qualification that ultimately lead to biomarker-based diagnostics.

Firalis team has expertise in discovery and development of biomarkers for driving the development of novel biomarker - based diagnostic kits for enabling the improvement of disease outcomes, the increase of patient comfort, better therapeutic decisions and the reduction of healthcare costs.

Our activities mainly, but not exclusively involve biomarkers that are related to inflammatory disorders including common diseases such as atherosclerosis, rheumatoid arthritis or rare/orphan diseases such as systemic or autoimmune vasculitis. A major part of our activities cover drug-induced organ injuries in particular kidney, liver and vasculature, as major drug targets.

Firalis team has been building a leading position via establishing a unique network of clinical centers of excellence for conducting clinical biomarker qualification studies.

We are solely investing on projects with high potential of success for biomarker-based diagnostics that will allow us to launch the first high-value diagnostic kits within short terms.

Huningue, “Passerelle de trois Pays” (Bridge of three countries )
(The longest pedestrians bridge of the World, on two foots with no intermediary support, “248 m.”)

 

The company is located in Huningue, a vibrant Alsatian town in the heart of Biovalley at the triple border of France, Germany and Switzerland.